1. Home
  2. PRTA vs GUT Comparison

PRTA vs GUT Comparison

Compare PRTA & GUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRTA
  • GUT
  • Stock Information
  • Founded
  • PRTA 2012
  • GUT 1999
  • Country
  • PRTA Ireland
  • GUT United States
  • Employees
  • PRTA N/A
  • GUT N/A
  • Industry
  • PRTA Biotechnology: Pharmaceutical Preparations
  • GUT Trusts Except Educational Religious and Charitable
  • Sector
  • PRTA Health Care
  • GUT Finance
  • Exchange
  • PRTA Nasdaq
  • GUT Nasdaq
  • Market Cap
  • PRTA 472.1M
  • GUT 535.8M
  • IPO Year
  • PRTA N/A
  • GUT N/A
  • Fundamental
  • Price
  • PRTA $9.92
  • GUT $5.92
  • Analyst Decision
  • PRTA Buy
  • GUT
  • Analyst Count
  • PRTA 9
  • GUT 0
  • Target Price
  • PRTA $13.14
  • GUT N/A
  • AVG Volume (30 Days)
  • PRTA 785.0K
  • GUT 176.3K
  • Earning Date
  • PRTA 11-11-2025
  • GUT 01-01-0001
  • Dividend Yield
  • PRTA N/A
  • GUT 10.93%
  • EPS Growth
  • PRTA N/A
  • GUT N/A
  • EPS
  • PRTA N/A
  • GUT N/A
  • Revenue
  • PRTA $10,341,000.00
  • GUT N/A
  • Revenue This Year
  • PRTA N/A
  • GUT N/A
  • Revenue Next Year
  • PRTA $602.32
  • GUT N/A
  • P/E Ratio
  • PRTA N/A
  • GUT N/A
  • Revenue Growth
  • PRTA N/A
  • GUT N/A
  • 52 Week Low
  • PRTA $4.32
  • GUT $4.60
  • 52 Week High
  • PRTA $18.88
  • GUT $7.38
  • Technical
  • Relative Strength Index (RSI)
  • PRTA 55.31
  • GUT 41.88
  • Support Level
  • PRTA $9.98
  • GUT $5.91
  • Resistance Level
  • PRTA $10.90
  • GUT $6.11
  • Average True Range (ATR)
  • PRTA 0.47
  • GUT 0.08
  • MACD
  • PRTA -0.06
  • GUT -0.01
  • Stochastic Oscillator
  • PRTA 23.93
  • GUT 24.00

About PRTA Prothena Corporation plc

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

About GUT Gabelli Utility Trust (The)

Gabelli Utility Trust operates as a diversified closed-end investment management company. The fund's primary objective is the long-term growth of capital and income. To achieve its objective, the fund may invest its assets in common stocks and other securities of foreign and domestic companies involved in providing products, services, or equipment for the generation or distribution of electricity, gas, & water; and telecommunications services or infrastructure operations. It invests in various sectors, of which Electric Integrated, Water, Telecommunications, and U.S. Government Obligations and others.

Share on Social Networks: